GCL
EUCR

Glazer Capital LLC’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Glazer Capital LLC’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,022,411
Closed -$10.2M – 615
2022
Q3 		$10.2M Buy
1,022,411
+696,605
+214% +$6.94M 0.19% 170
2022
Q2 		$3.22M Buy
325,806
+258,841
+387% +$2.56M 0.08% 274
2022
Q1 		$659K Sell
66,965
-25
-0% -$245 0.02% 352
2021
Q4 		$654K Buy
+66,990
New +$657K 0.02% 461

Other funds holding EUCR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Glazer Capital LLC's EUCR Position: Q4 2022 in Review

Glazer Capital LLC sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 1,022,411 shares — an estimated $10.2M sold.

Glazer Capital LLC first reported a position in EUCR in Q4 2021 and held it in 4 quarters. The position peaked at $10.2M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

  • Glazer Capital LLC reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Glazer Capital LLC sold 1,022,411 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $10.2M.
  • Glazer Capital LLC first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • Glazer Capital LLC's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $10.2M in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Glazer Capital LLC's 13F filing for Q4 2022, filed 14 Feb 2023.